Literature DB >> 8941637

Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction.

N Ashizawa1, K Graf, Y S Do, T Nunohiro, C M Giachelli, W P Meehan, T L Tuan, W A Hsueh.   

Abstract

Angiotensin II (AII) is a critical factor in cardiac remodeling which involves hypertrophy, fibroblast proliferation, and extracellular matrix production. However, little is known about the mechanism by which AII accelerates these responses. Osteopontin is an acidic phosphoprotein with RGD (arginine-glycine-aspartate) sequences that are involved in the vascular smooth muscle cell remodeling process. We identified the presence of osteopontin mRNA and protein in cultured rat cardiac fibroblasts and its prominent regulation by AII (10(-11) M). Osteopontin message levels were increased fourfold (P < 0.01) and protein fivefold (P < 0.05) at 24 h after addition of AII (10(-7) M). This response was inhibited by the AT1 receptor blocker, losartan. Osteopontin mRNA levels were increased in hypertrophied ventricles from animals with renovascular hypertension (1.6-fold, P < 0.05) and aortic banding (2.9-fold, P < 0.05). To examine the function of osteopontin, we determined its effects on (a) the ability of cardiac fibroblasts to contract three-dimensional collagen gels and (b) cardiac fibroblast growth. A monoclonal antibody against osteopontin partially blocked AII-induced three-dimensional collagen gel contraction by cardiac fibroblasts (64+/-4 vs. 86+/-5% in the presence of antibody, P < 0.05), while osteopontin itself promoted contraction of the gels by fibroblasts (71+/-5%, P < 0.05 compared with control). Either a monoclonal antibody against beta3 integrin which is a ligand for osteopontin or the RGD peptide blocked both AII and osteopontin-induced collagen gel contraction. Thus, the osteopontin RGD sequence binds to beta3 integrins on the fibroblast to promote fibroblast binding to collagen. All induced a threefold increase in DNA synthesis of cardiac fibroblasts, which was completely blocked by antibodies against osteopontin and beta3 integrin, or by RGD peptide, but not by controls. Thus, All-induced growth of cardiac fibroblasts also requires osteopontin engagement of the beta3 integrin. Taken together, these results provide the first evidence that osteopontin is a potentially important mediator of AII regulation of cardiac fibroblast behavior in the cardiac remodeling process.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8941637      PMCID: PMC507670          DOI: 10.1172/JCI119031

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  39 in total

1.  Glucocorticoids increase osteopontin expression in cardiac myocytes and microvascular endothelial cells. Role in regulation of inducible nitric oxide synthase.

Authors:  K Singh; J L Balligand; T A Fischer; T W Smith; R A Kelly
Journal:  J Biol Chem       Date:  1995-11-24       Impact factor: 5.157

2.  Interaction of osteopontin with fibronectin and other extracellular matrix molecules.

Authors:  B B Mukherjee; M Nemir; S Beninati; E Cordella-Miele; K Singh; I Chackalaparampil; V Shanmugam; M W DeVouge; A B Mukherjee
Journal:  Ann N Y Acad Sci       Date:  1995-04-21       Impact factor: 5.691

3.  Comparison of ANG II with other growth factors on Egr-1 and matrix gene expression in cardiac fibroblasts.

Authors:  K Iwami; N Ashizawa; Y S Do; K Graf; W A Hsueh
Journal:  Am J Physiol       Date:  1996-06

4.  Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat.

Authors:  B Schieffer; A Wirger; M Meybrunn; S Seitz; J Holtz; U N Riede; H Drexler
Journal:  Circulation       Date:  1994-05       Impact factor: 29.690

5.  Osteopontin expression is increased in the heritable cardiomyopathy of Syrian hamsters.

Authors:  E B Williams; I Halpert; S Wickline; G Davison; W C Parks; J N Rottman
Journal:  Circulation       Date:  1995-08-15       Impact factor: 29.690

6.  Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat.

Authors:  S J Sollott; L Cheng; R R Pauly; G M Jenkins; R E Monticone; M Kuzuya; J P Froehlich; M T Crow; E G Lakatta; E K Rowinsky
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

7.  Macrophages express osteopontin during repair of myocardial necrosis.

Authors:  C E Murry; C M Giachelli; S M Schwartz; R Vracko
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

8.  Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure. Marked upregulation of genes encoding extracellular matrix components.

Authors:  M O Boluyt; L O'Neill; A L Meredith; O H Bing; W W Brooks; C H Conrad; M T Crow; E G Lakatta
Journal:  Circ Res       Date:  1994-07       Impact factor: 17.367

9.  The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro.

Authors:  L Liaw; M P Skinner; E W Raines; R Ross; D A Cheresh; S M Schwartz; C M Giachelli
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

10.  Human osteoblast-like cells respond to mechanical strain with increased bone matrix protein production independent of hormonal regulation.

Authors:  L V Harter; K A Hruska; R L Duncan
Journal:  Endocrinology       Date:  1995-02       Impact factor: 4.736

View more
  50 in total

Review 1.  Extracellular Matrix in Ischemic Heart Disease, Part 4/4: JACC Focus Seminar.

Authors:  Nikolaos G Frangogiannis; Jason C Kovacic
Journal:  J Am Coll Cardiol       Date:  2020-05-05       Impact factor: 24.094

Review 2.  Matricellular proteins in cardiac adaptation and disease.

Authors:  Nikolaos G Frangogiannis
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

3.  Role of matricellular proteins in cardiac tissue remodeling after myocardial infarction.

Authors:  Yutaka Matsui; Junko Morimoto; Toshimitsu Uede
Journal:  World J Biol Chem       Date:  2010-05-26

4.  Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo.

Authors:  C M Giachelli; D Lombardi; R J Johnson; C E Murry; M Almeida
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

5.  Targeting the renin-angiotensin-aldosterone system in fibrosis.

Authors:  Mohammad AlQudah; Taben M Hale; Michael P Czubryt
Journal:  Matrix Biol       Date:  2020-05-16       Impact factor: 11.583

Review 6.  Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation.

Authors:  A O'Regan; J S Berman
Journal:  Int J Exp Pathol       Date:  2000-12       Impact factor: 1.925

Review 7.  A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme.

Authors:  Kenneth E Bernstein; Frank S Ong; Wendell-Lamar B Blackwell; Kandarp H Shah; Jorge F Giani; Romer A Gonzalez-Villalobos; Xiao Z Shen; Sebastien Fuchs; Rhian M Touyz
Journal:  Pharmacol Rev       Date:  2012-12-20       Impact factor: 25.468

8.  Extracellular matrix remodelling in myocardial hypertrophy and failure : focus on osteopontin.

Authors:  Pietro Francia; Arianna Uccellini; Alessandra Frattari; Anna Modestino; Agnese Ricotta; Cristina Balla; Ludovica Scialla; Massimo Volpe
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-01-03

Review 9.  Osteopontin: role in extracellular matrix deposition and myocardial remodeling post-MI.

Authors:  Mahipal Singh; Cerrone R Foster; Suman Dalal; Krishna Singh
Journal:  J Mol Cell Cardiol       Date:  2009-06-30       Impact factor: 5.000

10.  Defective peroxisomal proliferators activated receptor gamma activity due to dominant-negative mutation synergizes with hypertension to accelerate cardiac fibrosis in mice.

Authors:  Adrienn Kis; Colin Murdoch; Min Zhang; Anjana Siva; Sergio Rodriguez-Cuenca; Stefania Carobbio; Agnes Lukasik; Margaret Blount; Steve O'Rahilly; Sarah L Gray; Ajay M Shah; Antonio Vidal-Puig
Journal:  Eur J Heart Fail       Date:  2009-04-24       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.